We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , boasts of a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on central nervous system disorders, metabolic diseases, autoimmune diseases, cardiovascular diseases and cancer, which are all high growth areas and represent significant commercial potential.
Lilly’s earnings performance has been pretty impressive. Its earnings beat expectations in each of the last four quarters, with the average positive surprise being 10.03%.Estimates have remained stable ahead of earnings release
Currently, Lilly has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Lilly missed fourth quarter earnings. The company reported EPS of $1.33 per share while our consensus called for EPS of $1.36.
Revenues Beat: Revenues beat expectations. Lilly posted revenues of $6.44 billion, compared to our consensus estimate of $6.34 billion.
2019 Outlook Lowered: Lilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology and the decision to cease promotion of new drug Lartruvo.
The earnings forecast was reduced from a range of $5.90 to $6.00 to $5.55 to $5.65 per share. Lilly now expects revenues to be between $25.1 billion and $25.6 billion down from the prior expectations of $25.3 billion and $25.8 billion in 2019.
The Zacks Consensus Estimate for earnings and revenues is $5.87 per share and $25.38 billion, respectively.
Stock Price Impact: Shares were down around 2.5% in pre-market trading.
Check back later for our full write up on this Lilly earnings report later!
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View
Indianapolis, IN based Eli Lilly and Company (LLY - Free Report) , boasts of a wide range of products that serve a vast number of therapeutic areas. The company focuses primarily on central nervous system disorders, metabolic diseases, autoimmune diseases, cardiovascular diseases and cancer, which are all high growth areas and represent significant commercial potential.
Lilly’s earnings performance has been pretty impressive. Its earnings beat expectations in each of the last four quarters, with the average positive surprise being 10.03%.Estimates have remained stable ahead of earnings release
Currently, Lilly has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Miss: Lilly missed fourth quarter earnings. The company reported EPS of $1.33 per share while our consensus called for EPS of $1.36.
Revenues Beat: Revenues beat expectations. Lilly posted revenues of $6.44 billion, compared to our consensus estimate of $6.34 billion.
2019 Outlook Lowered: Lilly lowered its previously issued earnings and sales guidance for 2019 to account for the costs related to the pending acquisition of Loxo Oncology and the decision to cease promotion of new drug Lartruvo.
The earnings forecast was reduced from a range of $5.90 to $6.00 to $5.55 to $5.65 per share. Lilly now expects revenues to be between $25.1 billion and $25.6 billion down from the prior expectations of $25.3 billion and $25.8 billion in 2019.
The Zacks Consensus Estimate for earnings and revenues is $5.87 per share and $25.38 billion, respectively.
Stock Price Impact: Shares were down around 2.5% in pre-market trading.
Check back later for our full write up on this Lilly earnings report later!
Eli Lilly and Company Price and Consensus
Eli Lilly and Company Price and Consensus | Eli Lilly and Company Quote
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>